化疗和放射治疗对软组织肉 Sarcoma 的瘤缩的影响-它会影响预后吗?
Julian Fromm1,2, Alexander Klein1,2, Maya Kirilova1,2
1Department of Orthopaedics and Trauma Surgery, Orthopaedic Oncology, Musculoskeletal University Center Munich (MUM), LMU University Hospital, LMU Munich, Marchioninistr. 15, D- 81377, Munich, Germany.
BMC cancer
|March 6, 2024
概括
化学疗法和放射疗法等新辅助疗法在软组织肉瘤 (STSs) 中增加瘤缩. 然而,这种亡并不能持续改善STS的生存率或减少局部复发,这与骨肉瘤不同.
科学领域:
- 在瘤学瘤学.
- 手术病理学手术病理学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 软组织肉瘤 (STSs) 是一组多样化的癌症,通常通过手术治疗,通常与新辅助疗法结合.
- 虽然瘤亡是骨肉瘤的已知预后因素,但其在新辅助治疗后STS中的作用尚不清楚.
研究的目的:
- 调查新辅助化疗和放射治疗如何影响STSs中的瘤缩形成.
- 评估瘤亡对STS患者整体存活率和局部无复发存活率的影响.
- 为了比较STS患者与骨肉瘤 (BS) 患者和没有接受新辅助治疗的患者的发现.
主要方法:
- 对779名经过手术治疗的STS或BS患者的回顾性分析.
- 关于瘤特异性因素 (类型,大小,等级) 和辅助治疗细节的文件.
- 在随访期间评估局部复发 (LR),转移性疾病诊断和生存结果.
主要成果:
- 在接受新辅助疗法 (53.5%) 的STS患者中,瘤缩显著高于未接受新辅助疗法 (15.7%) 的患者 (53.5%).
- 结合的新辅助化疗和放射治疗导致瘤死亡率高于单独的放射治疗.
- 瘤亡与改善的整体存活率或减少STS局部复发无关,除了在没有新辅助治疗的G2/3STS亚组之外.
结论:
- 新辅助化疗和/或放射疗法在STS中增强瘤缩,组合疗法显示出最明显的效果.
- 与骨肉瘤不同的是,在新辅助疗法后的软组织肉瘤中,瘤缩不会预测更好的生存率或更低的局部复发率.
- 瘤分级显著影响亡率,但STS中亡的预后值与骨肉瘤的预后值不同.
相关概念视频
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K